Equities

Neuronetics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Neuronetics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.25
  • Today's Change-0.040 / -3.11%
  • Shares traded317.72k
  • 1 Year change-70.66%
  • Beta0.9425
Data delayed at least 15 minutes, as of Mar 03 2026 15:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.

  • Revenue in USD (TTM)129.87m
  • Net income in USD-44.50m
  • Incorporated2001
  • Employees716.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Outset Medical Inc119.48m-81.65m65.37m310.00--0.5109--0.5472-6.78-6.787.876.990.44231.363.74385,406.40-30.23-37.90-35.71-43.8239.1324.03-68.34-116.475.40-10.190.4312--5.0919.0636.20---38.55--
Accuray Inc436.97m-35.62m65.51m990.00--1.23--0.1499-0.2982-0.29823.890.44970.94342.105.82441,382.80-7.69-1.60-13.56-2.7227.8335.04-8.15-1.750.7091-0.51930.7178--2.683.6789.77--2.76--
Neuraxis Inc3.36m-8.37m67.11m21.00--27.30--19.96-1.02-1.020.40590.23110.97187.9441.74160,111.00-217.93---1,360.57--84.34---224.24--1.55-97.220.0789--9.18--42.21------
DarioHealth Corp24.73m-37.11m72.65m196.00--0.971--2.94-12.47-12.478.2911.070.21732.226.51126,183.70-37.17-63.89-42.41-75.3056.8634.31-171.09-262.344.02-69.690.2901--32.8629.0435.47--7.09--
QT Imaging Holdings Inc18.92m-21.08m72.87m20.00--11.28--3.85-2.21-2.211.810.54151.302.536.47---144.85---368.39--45.36---111.40--2.17-1.750.4158--287.91---48.78------
Sensus Healthcare Inc35.61m-3.01m75.57m35.00--1.47--2.12-0.1847-0.18472.183.110.60281.322.711,017,400.00-5.0913.01-5.6614.9847.9561.32-8.4419.455.27--0.00--71.318.931,270.52---7.18--
Positron Corp1.24m-1.27m75.69m22.00------61.19-0.0897-0.08970.0876-0.11090.59762.296.56---61.35-224.13----32.989.85-102.67-201.870.0638-------10.060.275163.63--4.36--
InspireMD Inc7.78m-46.20m77.54m85.00--1.20--9.97-0.8396-0.83960.1391.530.12071.934.4691,517.65-71.65-60.63-83.34-71.7724.9120.76-593.89-377.986.17--0.00--12.9613.50-60.70--37.62--
Picard Medical Inc4.77m-33.80m79.60m75.00--9.99--16.67-0.4673-0.46730.0660.1081------63,653.33---------10.03---660.85--0.9373-0.78080.0134---12.93---31.86------
Xtant Medical Holdings Inc133.08m1.75m80.00m217.0055.911.5911.970.60110.01020.01020.91580.35991.301.225.78613,285.701.71-11.382.57-16.1762.0259.371.32-9.641.061.570.3635--28.4412.64-2,592.27--36.16--
MaxCyte Inc34.42m-45.63m84.07m114.00--0.4662--2.44-0.4298-0.42980.32431.690.1490.76575.35301,921.10-19.75-13.01-21.30-14.0179.9787.32-132.58-72.437.27--0.00---6.4412.31-8.26--5.37--
Neuronetics Inc129.87m-44.50m88.35m716.00--3.23--0.6803-0.8344-0.83442.240.39971.1813.877.31181,386.90-40.63-29.61-52.56-36.9650.4374.98-34.35-53.712.09-4.310.6768--4.963.63-44.78--12.51--
Vivani Medical Inc0.00-26.03m99.07m42.00--57.33-----0.4417-0.44170.000.02130.00----0.00-76.61-43.12-94.91-49.69------------0.00------8.44--2.43--
Baird Medical Investment Holdings Ltd31.86m-3.12m103.20m143.00--2.10--3.24-0.1128-0.11281.221.340.45523.270.8459222,797.30-4.48---7.64--86.94---9.84--1.67-0.3230.3856--17.74--18.57------
Hyperfine Inc10.59m-40.05m106.67m111.00--3.17--10.07-0.5243-0.52430.13850.33390.1910.88591.8195,414.41-72.23-45.05-88.25-48.8646.1230.47-378.17-757.553.06--0.00--16.84--7.95--9.44--
Treace Medical Concepts Inc212.69m-59.00m107.22m450.00--1.22--0.5041-0.9338-0.93383.361.361.041.145.13472,644.40-28.95-25.72-34.49-30.9579.8180.88-27.74-26.933.13-21.300.3889--1.5929.96-5.85--66.10--
Data as of Mar 03 2026. Currency figures normalised to Neuronetics Inc's reporting currency: US Dollar USD

Institutional shareholders

24.02%Per cent of shares held by top holders
HolderShares% Held
UBS Securities LLCas of 31 Dec 20252.61m3.94%
Balyasny Asset Management LPas of 31 Dec 20252.55m3.86%
The Vanguard Group, Inc.as of 31 Dec 20252.31m3.49%
BlackRock Fund Advisorsas of 31 Dec 20252.17m3.28%
Lane Generational LLCas of 31 Dec 20251.71m2.58%
Jane Street Capital LLCas of 31 Dec 20251.02m1.54%
Masters Capital Management LLCas of 31 Dec 20251.00m1.51%
FourWorld Capital Management LLCas of 31 Dec 2025931.25k1.41%
Geode Capital Management LLCas of 31 Dec 2025891.73k1.35%
Ikarian Capital LLCas of 31 Dec 2025701.18k1.06%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.